


PHARMACEUTICAL 2021



Cyclerion Therapeutics Inc. Rank 302 of 409





PHARMACEUTICAL 2021



Cyclerion Therapeutics Inc. Rank 302 of 409

The relative strengths and weaknesses of Cyclerion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cyclerion Therapeutics Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 222% points. The greatest weakness of Cyclerion Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 186% points.

The company's Economic Capital Ratio, given in the ranking table, is -314%, being 41% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	58,501
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,952
Liabilities, Non-Current	0
Other Assets	50,012
Other Compr. Net Income	-7.0
Other Expenses	-1,669
Other Liabilities	0
Other Net Income	3,463
Property and Equipment	6,865
Research and Development	56,414
Revenues	2,296
Selling, General and Administrative Expense	28,816

Output Variable	Value in 1000 USD
Assets	115,378
Liabilities	16,952
Expenses	83,561
Stockholders Equity	98,426
Net Income	-77,802
Comprehensive Net Income	-77,806
Economic Capital Ratio	-314%